METHODS AND GENE EXPRESSION SIGNATURE FOR ASSESSING RAS PATHWAY ACTIVITY

• US 20100280987A1
• Filed: 04/16/2010
• Published: 11/04/2010
• Est. Priority Date: 04/18/2009
• Status: Abandoned Application

• Current Assignee: Merck Sharp & Dohme Corporation (Merck & Co., Inc.)
• Original Assignee: Merck Sharp & Dohme Corporation (Merck & Co., Inc.)
• Inventors: Klinghoffer, Richard A., Watters, James W., Huang, Pearl S., Chastain, Michael, Nebozhyn, Michael, Loboda, Andrey, Zhang, Theresa
• Application Number:
  US12/761,772
• Publication Number:
  US 20100280987A1
• Time in Patent Office: Days
• US Class Current: 706/54
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/106 Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
• CPC Class Codes: G16B 20/00 ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
• CPC Class Codes: G16B 20/20 Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
• CPC Class Codes: G16B 25/00 ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
• CPC Class Codes: G16B 25/10 Gene or protein expression profiling; Expression-ratio estimation or normalisation

Abstract

Methods, biomarkers, and expression signatures are disclosed for assessing the regulation status of RAS pathway signaling in a cell sample or subject. More specifically, several aspects of the invention provide a set of genes which can be used as biomarkers and gene signatures for evaluating RAS pathway deregulation status in a sample; classifying a cell sample as having a deregulated or regulated RAS signaling pathway; determining whether an agent modulates the RAS signaling pathway in sample; predicting response of a subject to an agent that modulates the RAS signaling pathway; assigning treatment to a subject; and evaluating the pharmacodynamic effects of cancer therapies designed to regulate RAS pathway signaling.

Claims

1. A method for predicting response of an human subject to an agent that modulates the RAS signaling pathway, said method comprising:

(a) classifying said human subject as having a deregulated or regulated RAS signaling pathway, wherein said classifying comprises;

(i) calculating a measure of similarity between a first expression profile and a regulated RAS signaling pathway template, said first expression profile comprising the expression levels of a first plurality of genes in an isolated cell sample derived from said human subject, said regulated RAS signaling pathway template comprising expression levels of said first plurality of genes that are average expression levels of the respective genes in a plurality of human control cell samples not having at least one or more components of said RAS signaling pathway with abnormal activity, said first plurality of genes consisting of at least 5 of the genes for which biomarkers are listed in Tables 2a and 2b, wherein at least 1 gene of said 5 genes is selected from Table 2b;

(ii) classifying said cell sample as having said regulated RAS signaling pathway if said first expression profile has a high similarity to said regulated RAS signaling pathway template, or classifying said cell sample as having said deregulated RAS signaling pathway if said first expression profile has a low similarity to said regulated RAS signaling pathway template;

wherein said first expression profile has a high similarity to said regulated RAS signaling pathway template if the similarity to said regulated RAS signaling pathway template is above a predetermined threshold, or has a low similarity to said regulated RAS signaling pathway template if the similarity to said regulated RAS signaling pathway template is below said predetermined threshold; and

(iii) displaying;

or outputting to a user, user interface device, a computer readable storage medium, or a local or remote computer system;

the classification produced by said classifying step (ii);

wherein said human subject is predicted to respond to said agent if said cell sample is classified as having a deregulated RAS signaling pathway.

2. A method for predicting response of an human subject to an agent that modulates the RAS signaling pathway, said method comprising:

(a) classifying said human subject as having a deregulated or regulated RAS signaling pathway, wherein said classifying comprises;

(i) calculating a signature score by a method comprising;

a) calculating a differential expression value of a first expression level of each of a first plurality of genes and each of a second plurality of genes in an isolated cell sample derived from said human subject relative to a second expression level of each of said first plurality of genes and each of said second plurality of genes in an human control cell sample, said first plurality of genes consisting of at least 3 or more of the genes for which biomarkers are listed in Table 2a and said second plurality of genes consisting of at least 3 or more of the genes for which biomarkers are listed in Table 2b;

b) calculating the mean differential expression values of the expression levels of said first plurality of genes and said second plurality of genes; and

c) subtracting said mean differential expression value of said second plurality of genes from said mean differential expression value of said first plurality of genes to obtain said signature score;

(ii) classifying said cell sample as having a deregulated RAS signaling pathway;

a) if said obtained signature score is above a predetermined threshold, and b) if said signature score is statistically significant; and

(iii) displaying;

or outputting to a user, user interface device, a computer readable storage medium, or a local or remote computer system;

the classification produced by said classifying step (ii);

wherein said human subject is predicted to respond to said agent if said cell sample is classified as having a deregulated RAS signaling pathway.

3. The method of claim 2, wherein said first plurality of genes consists of at least 5 or more of the genes for which biomarkers are listed in Table 2a and said second plurality of genes consists of at least 5 or more genes for which biomarkers are listed in Table 2b.

4. The method of claim 2, wherein said first plurality of genes consists of at least 10 or more of the genes for which biomarkers are listed in Table 2a and said second plurality of genes consists of at least 10 or more genes for which biomarkers are listed in Table 2b.

5. The method of claim 2, wherein said first plurality of genes consists of at least 20 or more of the genes for which biomarkers are listed in Table 2a and said second plurality of genes consists of at least 20 or more genes for which biomarkers are listed in Table 2b.

6. The method of claim 2, wherein said first plurality of genes consists of all of the genes listed in Table 2a and said second plurality of genes consists of all of the genes for which biomarkers are listed in Table 2b.

7. The method of claim 2, wherein said differential expression value is log(10) ratio.

8. The method of claim 2, wherein said threshold is 0.

9. The method of claim 2, wherein said signature scores is statistically significant if it has a p-value less than 0.05.

10. The method of claim 2, wherein said agent is a MEK inhibitor.

11. A method for predicting response of an human subject to an agent that modulates the PI3K signaling pathway, said method comprising:

(a) classifying said human subject as having a deregulated or regulated RAS signaling pathway, wherein said classifying comprises;

(i) calculating a signature score by a method comprising;

a) calculating a differential expression value of a first expression level of each of a first plurality of genes and each of a second plurality of genes in an isolated cell sample derived from said human subject relative to a second expression level of each of said first plurality of genes and each of said second plurality of genes in an human control cell sample, said first plurality of genes consisting of at least 3 or more of the genes for which biomarkers are listed in Table 2a and said second plurality of genes consisting of at least 3 or more of the genes for which biomarkers are listed in Table 2b;

b) calculating the mean differential expression values of the expression levels of said first plurality of genes and said second plurality of genes; and

c) subtracting said mean differential expression value of said second plurality of genes from said mean differential expression value of said first plurality of genes to obtain said signature score;

(ii) classifying said cell sample as having a deregulated RAS signaling pathway a) if said obtained signature score is above a predetermined threshold, and b) if said signature score is statistically significant; and

(iii) displaying;

or outputting to a user, user interface device, a computer readable storage medium, or a local or remote computer system;

the classification produced by said classifying step (ii);

wherein said human subject is predicted to respond to said agent if said cell sample is classified as having a deregulated RAS signaling pathway.

12. The method of claim 11, wherein said first plurality of genes consists of at least 5 or more of the genes for which biomarkers are listed in Table 2a and said second plurality of genes consists of at least 5 or more genes for which biomarkers are listed in Table 2b.

13. The method of claim 11, wherein said first plurality of genes consists of at least 10 or more of the genes for which biomarkers are listed in Table 2a and said second plurality of genes consists of at least 10 or more genes for which biomarkers are listed in Table 2b.

14. The method of claim 11, wherein said first plurality of genes consists of at least 20 or more of the genes for which biomarkers are listed in Table 2a and said second plurality of genes consists of at least 20 or more genes for which biomarkers are listed in Table 2b.

15. The method of claim 11, wherein said first plurality of genes consists of all of the genes listed in Table 2a and said second plurality of genes consists of all of the genes for which biomarkers are listed in Table 2b.

16. The method of claim 11, wherein said differential expression value is log(10) ratio.

17. The method of claim 11, wherein said threshold is 0.

18. The method of claim 11, wherein said signature scores is statistically significant if it has a p-value less than 0.05.

19. The method of claim 11, wherein said agent is a PI3K inhibitor.

20. The method of claim 11, wherein said agent is an AKT inhibitor.

21. A method of assigning treatment to an human subject, said method comprising:

(a) classifying said human subject as having a deregulated or regulated RAS signaling pathway, wherein said classifying comprises;

(i) calculating a signature score by a method comprising;

a) calculating a differential expression value of a first expression level of each of a first plurality of genes and each of a second plurality of genes in an isolated cell sample derived from said human subject relative to a second expression level of each of said first plurality of genes and each of said second plurality of genes in an human control cell sample, said first plurality of genes consisting of at least 3 or more of the genes for which biomarkers are listed in Table 2a and said second plurality of genes consisting of at least 3 or more of the genes for which biomarkers are listed in Table 2b;

b) calculating the mean differential expression values of the expression levels of said first plurality of genes and said second plurality of genes; and

c) subtracting said mean differential expression value of said second plurality of genes from said mean differential expression value of said first plurality of genes to obtain said signature score;

(ii) classifying said cell sample as having a deregulated RAS signaling pathway a) if said obtained signature score is above a predetermined threshold, and b) if said signature score is statistically significant; and

(iii) displaying;

or outputting to a user, user interface device, a computer readable storage medium, or a local or remote computer system;

the classification produced by said classifying step (ii);

(b) assigning said human subject for treatment with an agent that modulates the RAS signaling pathway, if said cell sample is classified as having deregulated RAS signaling pathway.

22. The method of claim 21, wherein said first plurality of genes consists of at least 5 or more of the genes for which biomarkers are listed in Table 2a and said second plurality of genes consists of at least 5 or more genes for which biomarkers are listed in Table 2b.

23. The method of claim 21, wherein said first plurality of genes consists of at least 10 or more of the genes for which biomarkers are listed in Table 2a and said second plurality of genes consists of at least 10 or more genes for which biomarkers are listed in Table 2b.

24. The method of claim 21, wherein said first plurality of genes consists of at least 20 or more of the genes for which biomarkers are listed in Table 2a and said second plurality of genes consists of at least 20 or more genes for which biomarkers are listed in Table 2b.

25. The method of claim 21, wherein said first plurality of genes consists of all of the genes listed in Table 2a and said second plurality of genes consists of all of the genes for which biomarkers are listed in Table 2b.

26. The method of claim 21, wherein said differential expression value is log(10) ratio.

27. The method of claim 21, wherein said threshold is 0.

28. The method of claim 21, wherein said signature scores is statistically significant if it has a p-value less than 0.05.

29. The method of claim 21, wherein said agent is a MEK inhibitor.

30. A method of assigning treatment to an human subject, said method comprising:

(a) classifying said human subject as having a deregulated or regulated RAS signaling pathway, wherein said classifying comprises;

(i) calculating a signature score by a method comprising;

a) calculating a differential expression value of a first expression level of each of a first plurality of genes and each of a second plurality of genes in an isolated cell sample derived from said human subject relative to a second expression level of each of said first plurality of genes and each of said second plurality of genes in an human control cell sample, said first plurality of genes consisting of at least 3 or more of the genes for which biomarkers are listed in Table 2a and said second plurality of genes consisting of at least 3 or more of the genes for which biomarkers are listed in Table 2b;

b) calculating the mean differential expression values of the expression levels of said first plurality of genes and said second plurality of genes; and

c) subtracting said mean differential expression value of said second plurality of genes from said mean differential expression value of said first plurality of genes to obtain said signature score;

(ii) classifying said cell sample as having a deregulated RAS signaling pathway a) if said obtained signature score is above a predetermined threshold, and b) if said signature score is statistically significant; and

(iii) displaying;

or outputting to a user, user interface device, a computer readable storage medium, or a local or remote computer system;

the classification produced by said classifying step (ii);

(b) not assigning said human subject for treatment with an agent that modulates the PI3K signaling pathway, if said cell sample is classified as having deregulated RAS signaling pathway.

31. The method of claim 30, wherein said first plurality of genes consists of at least 5 or more of the genes for which biomarkers are listed in Table 2a and said second plurality of genes consists of at least 5 or more genes for which biomarkers are listed in Table 2b.

32. The method of claim 30, wherein said first plurality of genes consists of at least 10 or more of the genes for which biomarkers are listed in Table 2a and said second plurality of genes consists of at least 10 or more genes for which biomarkers are listed in Table 2b.

33. The method of claim 30, wherein said first plurality of genes consists of at least 20 or more of the genes for which biomarkers are listed in Table 2a and said second plurality of genes consists of at least 20 or more genes for which biomarkers are listed in Table 2b.

34. The method of claim 30, wherein said first plurality of genes consists of all of the genes listed in Table 2a and said second plurality of genes consists of all of the genes for which biomarkers are listed in Table 2b.

35. The method of claim 30, wherein said differential expression value is log(10) ratio.

36. The method of claim 30, wherein said threshold is 0.

37. The method of claim 30, wherein said signature scores is statistically significant if it has a p-value less than 0.05.